CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025
Company's AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models.
Article content
Article content
MOUNT LAUREL, N.J. — CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago.
Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata ®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta ®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved only for newly diagnosed AML. Quizartinib does not target TKD resistance mutations, whereas Gilteritinib's efficacy on FLT3-ITD-D835 mutations is limited and it is not effective against the FLT3-ITD-F691 gatekeeper mutation, both of which are very common. Crenolanib (AROG/Pfizer) is an FLT3 inhibitor whose NDA submitted to the FDA does not address the indications above, whose NDA was previously rejected by the FDA, and which binds to FLT3 mutants less tightly than Gilteritinib. Consequently, there is a critical need for next-generation FLT3 inhibitors that can address all of these mutations.
Article content
At ASCO 2025, CCM Biosciences' presentation 'Novel, Potent and Selective Inhibitors Targeting FLT3 for AML Therapy' in the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant session (Abstract #: 6542, https://www.asco.org/abstracts-presentations/ABSTRACT502974) will report novel FLT3 inhibitors have been identified that can both target FLT3-ITD and potentially overcome mutational resistance to FDA-approved FLT3 inhibitors. These agents are significantly more effective than Gilteritinib and have significant potential clinical applications.
Article content
CCM Biosciences' novel, orally bioavailable FLT3 inhibitors (CCM-405 and CCM-445) are the first drug candidates to overcome both FLT3-ITD juxtamembrane domain and tyrosine kinase domain (TKD) mutational drug resistance (including D835Y, F691L), significantly outperforming the aforementioned current-generation inhibitors both in the absence and presence of resistance mutations. Other reported investigational drug candidates capable of addressing FLT3-ITD resistance mutations either have poor pharmacokinetics, significant off-target binding, or both.
Article content
CCM Biosciences is advancing clinical candidates from its FLT3 inhibitor program to investigational new drug (IND) filing this year for entry into clinical trials for both newly diagnosed FLT3-positive AML and relapsed/refractory FLT3-positive AML. Multiple failures in AML clinical trials from competitors in 2024 present an attractive landscape for clinical trials of these drug candidates.
Article content
The company is actively partnering with biotechnology and pharmaceutical companies for co-development rights in selected countries. CCM Biosciences, a sister company of the global chemical and pharmaceutical services company PMC Group, Inc., is also a Featured Exhibitor at ASCO 2025 — https://asco25.myexpoonline.com/co/ccm-biosciences — and will be showcasing both its drug programs and the state-of-the-art platforms used to discover and develop them.
Article content
About CCM Biosciences
CCM Biosciences is a diversified biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines within multiple corporate subsidiaries. CCM's patented drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, Physical Review, American Chemical Society journals, Biophysical Society journals, and Nature Publishing Group journals. These platforms are complemented by the contract research, development, and manufacturing organizations (CRDMO) at PMC Group, the sister company of CCM Biosciences and a global chemical and pharmaceutical company with ~$1 billion in annual revenue.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 minutes ago
- Globe and Mail
NANO Nuclear Energy Advances to U.S. Army xTechSearch 9 Finals Pitch Event
New York, New York--(Newsfile Corp. - August 21, 2025) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or the "Company"), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that it has been selected by the U.S. Army's xTech program to advance to the finals pitch event of the prestigious U.S. Army xTechSearch 9 competition. To view an enhanced version of this graphic, please visit: "We are honored to be recognized by the U.S. Army through the xTech program and excited to advance to the final pitch," said Jay Yu, Founder and Chairman of NANO Nuclear. "This milestone underscores the potential of our technologies, particularly our deployable microreactor, to support the Army's mission and national security priorities. We look forward to presenting our vision and capabilities at the finals." "The selection into the xTechSearch 9 finals highlights the growing interest in our deployable microreactor, to deliver resilient and sustainable power in contested and austere environments," said James Walker, Chief Executive Officer of NANO Nuclear. "We are eager to continue the process, share our progress with Army stakeholders, and explore opportunities for future collaboration." The xTech program is a competitive initiative led by the U.S. Army to engage with innovative technology companies and foster dual-use solutions that can meet critical defense needs. Advancing to the finals provides NANO Nuclear the opportunity to showcase its capabilities directly to Army decision-makers and continue discussions on how its advanced microreactors may enhance operational energy resilience and logistical flexibility. Follow U.S. Army XTECH @: About NANO Nuclear Energy, Inc. NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S. Led by a world-class nuclear engineering team, NANO Nuclear's reactor products in development include patented KRONOS MMR ™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign (U. of I.), " ZEUS", a solid core battery reactor, and " ODIN", a low-pressure coolant reactor, and the space focused, portable LOKI MMR ™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors. Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, is led by former executives from the largest transportation company in the world aiming to build a North American transportation company that will provide commercial quantities of HALEU fuel to small modular reactors, microreactor companies, national laboratories, military, and DOE programs. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. Assuming development and commercialization, AFT is expected to form part of the only vertically integrated nuclear fuel business of its kind in North America. HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry. NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear's developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR ™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS' initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface. For more corporate information please visit: PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE: NANO Nuclear Energy LINKEDIN NANO Nuclear Energy YOUTUBE NANO Nuclear Energy X PLATFORM Cautionary Note Regarding Forward-Looking Statements This news release and statements of NANO Nuclear's management in connection with this news release contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "seek," "expects", "anticipates", "intends", "plans", "believes", "potential", "will", "should", "could", "would" or "may" and other words of similar meaning. In this press release, forward-looking statements relate to the anticipated benefits of NANO Nuclear's participation in the xTechSearch 9 competition (which NANO Nuclear may or may not win), as well statements related NANO Nuclear's development, construction, regulatory licensing and commercialization plans and goals. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. Readers are also cautioned that actual results may differ materially and adversely from the results implied in forward-looking statements. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy ("DOE"), U.S. Nuclear Regulatory Commission ("NRC") or related state or non-U.S. nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complimentary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain contracts and funding to be able to continue operations, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 executives orders seeking to streamline the nuclear regulatory process, and (vi) similar risks and uncertainties associated with the operating an early stage business a highly regulated and rapidly evolving industry. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at and at Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
National Post
2 minutes ago
- National Post
Ohio's Southwest Local School District Modernizes Procurement and Invoicing with Euna Solutions
Article content SWLSD achieves faster approvals, 25% cost savings, and full digitization with Euna's cloud-based tools Article content ATLANTA & TORONTO — Euna Solutions®, a leading provider of best-in-class SaaS solutions, purpose-built for the public sector, today announced that Southwest Local School District (SWLSD) in Ohio has successfully modernized its procurement and invoicing operations using Euna Procurement's Marketplace and Invoicing modules. Fully integrated with the district's ERP system, the new digital-first tools have reduced manual workloads, improved accuracy, and enhanced financial transparency. Article content 'Before Euna, we were filing stacks of paper and manually retyping invoices and requisitions, which created unnecessary delays and clerical errors,' said Roger McGregor, Treasurer at SWLSD. 'Now, we've completely streamlined those processes—teachers can order what they need online, and invoices are automatically matched and processed. It's a night-and-day improvement.' Article content Procurement: 25% Cost Savings and Faster Approvals Article content Previously relying on paper-based requisitions and manual approvals, SWLSD implemented Euna Procurement's Marketplace as part of a broader district-wide digital modernization effort. Teachers and staff are now able to browse digital vendor catalogs, submit purchase requests online, and benefit from automated workflows and real-time data that integrates into SWLSD's existing ERP system for seamless financial tracking and reconciliation. The district saw a 25% cost savings on eligible purchases in their first year of using Euna Marketplace, processing over 1,200 orders and tracking more than $315,000 in spend through the solution. Article content Procurement approvals are now 60% faster, averaging just 1–2 days. AI-powered savings recommendations within Euna Marketplace helped SWLSD save 25% on eligible purchases compared to baseline pricing. Article content Invoicing: Eliminated Paper and Improved Accuracy Article content The district also replaced its paper-heavy invoicing process with Euna Marketplace's Invoicing module. Instead of retyping and filing physical invoices, staff members now process hundreds of invoices with greater efficiency. In 2024, SWLSD processed 2,821 invoices through the system, fully eliminating printed invoices and enabling real-time tracking of payments. Article content 'The ability to instantly find any invoice in the system—not search through a file box—is a huge time saver,' added McGregor. 'It also gives our leadership clear, real-time visibility into spending and outstanding payments.' Article content A Model for K–12 Modernization Article content SWLSD's success reflects a growing shift in K–12 procurement toward automation and integration where AI-enabled platforms are leading the way in driving cost savings and operational efficiency in public education. With Euna Procurement's Marketplace and Invoicing solutions, SWLSD joins a growing number of districts modernizing financial operations to increase transparency and reduce administrative burden. Article content 'Southwest Local School District's journey exemplifies what we strive for at Euna Solutions: simplifying complexity and enabling our public sector partners to drive efficiency while operating smoothly and transparently,' said Brian Haney, Chief Customer Officer at Euna Solutions. 'Through intuitive tools like Euna Marketplace, we help districts unlock time and cost savings so they can focus on their mission, not manual processes. It's about empowering organizations to serve their communities better, building trust, and creating the kind of operational environment where both staff members and constituents can thrive.' Article content To learn more about Euna Procurement and its cloud-based tools, visit: About Euna Solutions Euna Solutions® is a leading provider of purpose-built, cloud-based software that helps public sector and government organizations streamline procurement, budgeting, payments, grants management, and special education administration. Designed to enhance efficiency, collaboration, and compliance, Euna Solutions supports more than 3,400 organizations across North America in building trust, enabling transparency, and driving community impact. Recognized on Government Technology's GovTech 100 list, Euna Solutions is committed to advancing public sector progress through innovative SaaS solutions. To learn more, visit Article content Article content Article content Article content Article content Contacts Article content
Globe and Mail
27 minutes ago
- Globe and Mail
Ducommun to Participate in Jefferies Industrials Conference
COSTA MESA, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ducommun Incorporated (NYSE: DCO) ('Ducommun' or the 'Company') announced today that Stephen G. Oswald, the Company's chairman, president and chief executive officer will participate in the upcoming Jefferies Industrials Conference on September 3, 2025. A general presentation will be held at 3:30 p.m. Eastern, with one-on-one investor meetings scheduled throughout the day. Additional information will be posted on the Company's website at when available, including a copy of any presentation material. A live webcast of the presentation can be accessed using this link. A replay of the webcast will be available on the Ducommun website at Institutional investors are welcome to contact Jefferies to arrange one-on-one calls with management. About Ducommun Incorporated Ducommun Incorporated delivers value-added innovative products and manufacturing solutions to customers in the aerospace, defense and industrial markets. Founded in 1849, the Company specializes in two core areas - Electronic Systems and Structural Systems - to produce complex products and components for commercial aircraft platforms, mission-critical military and space programs, and sophisticated industrial applications. For more information, visit
